Organogenesis Prepares To Restructure In The Face Of New CMS Skin-Substitute Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
The maker of Apligraf for foot ulcers and venous leg ulcers is facing a more than 30% reduction in Medicare reimbursement starting Jan. 1. Organogenesis’ CEO says the firm is readying a plan to significantly trim its business costs so it can continue to market the PMA-approved, bioengineered product.